

Minerva Neurosciences, Inc. Investor Relations Department 1601 Trapelo Road Suite 284 Waltham, MA 02451 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: NERV	
Last Trade:	5.85
Trade Time:	4:00 PM ET Aug 21, 2017
Change:	-0.10 ♣ (- 1.681%)
Day Range	5.75 - 6.00
52-Week Range	5.85 - 14.92
Volume	137,269

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Minerva Neurosciences. Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is... (more)

Stock Performance



Press Releases [View all]

Aug 3, 2017

Minerva Neurosciences Reports Second
Quarter 2017 Financial Results and Business
Updates

Jul 31, 2017

American Journal of Psychiatry Publishes

Minerva Neurosciences' MIN-101 Phase 2b

Trial Results for Treatment of Negative

Symptoms in Schizophrenia

Jul 27, 2017

Minerva Neurosciences to Report Second
Quarter 2017 Financial Results and Business
Updates on August 3, 2017

Jul 24, 2017

Minerva Neurosciences Announces
Departure of Directors

Jul 5, 2017

Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Financials [View all]

Second Quarter Financial Results

Mar 13, 2017

Annual Report (10-K)

Apr 18, 2017

Proxy Statement (DEF 14A)

Aug 3, 2017

Quarterly Report (10-Q)

May 4, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)